Eurobio Scientific Société anonyme Future Growth
Future criteria checks 3/6
Eurobio Scientific Société anonyme is forecast to grow earnings and revenue by 29% and 3.9% per annum respectively. EPS is expected to grow by 30.9% per annum. Return on equity is forecast to be 10.5% in 3 years.
Key information
29.0%
Earnings growth rate
30.9%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 3.9% |
| Future return on equity | 10.5% |
| Analyst coverage | Low |
| Last updated | 25 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 156 | 15 | 25 | 27 | 1 |
| 12/31/2025 | 148 | 11 | 21 | 24 | 1 |
| 12/31/2024 | 138 | 9 | 17 | 20 | 1 |
| 6/30/2024 | 145 | 7 | 20 | 23 | N/A |
| 3/31/2024 | 138 | 6 | 21 | 25 | N/A |
| 12/31/2023 | 131 | 5 | 23 | 27 | N/A |
| 9/30/2023 | 129 | 6 | 23 | 28 | N/A |
| 6/30/2023 | 128 | 8 | 24 | 29 | N/A |
| 3/31/2023 | 140 | 16 | 32 | 36 | N/A |
| 12/31/2022 | 153 | 25 | 40 | 43 | N/A |
| 9/30/2022 | 163 | 36 | N/A | N/A | N/A |
| 6/30/2022 | 174 | 47 | 60 | 61 | N/A |
| 3/31/2022 | 180 | 54 | 62 | 64 | N/A |
| 12/31/2021 | 185 | 61 | 64 | 66 | N/A |
| 9/30/2021 | 204 | 71 | N/A | N/A | N/A |
| 6/30/2021 | 223 | 81 | 83 | 85 | N/A |
| 3/31/2021 | 206 | 77 | 68 | 70 | N/A |
| 12/31/2020 | 189 | 73 | 53 | 55 | N/A |
| 9/30/2020 | 141 | 51 | 29 | 30 | N/A |
| 6/30/2020 | 92 | 28 | 5 | 5 | N/A |
| 3/31/2020 | 76 | 16 | 4 | 5 | N/A |
| 12/31/2019 | 59 | 3 | 3 | 5 | N/A |
| 9/30/2019 | 58 | 1 | 2 | 3 | N/A |
| 6/30/2019 | 56 | -2 | 0 | 2 | N/A |
| 3/31/2019 | 53 | -2 | -1 | 1 | N/A |
| 12/31/2018 | 51 | -3 | -2 | -1 | N/A |
| 9/30/2018 | 50 | -4 | -3 | 0 | N/A |
| 6/30/2018 | 48 | -6 | -4 | 1 | N/A |
| 3/31/2018 | 46 | -8 | N/A | 2 | N/A |
| 12/31/2017 | 43 | -10 | N/A | 2 | N/A |
| 9/30/2017 | 38 | -9 | N/A | 0 | N/A |
| 6/30/2017 | 32 | -9 | N/A | -2 | N/A |
| 3/31/2017 | 30 | -8 | N/A | -2 | N/A |
| 12/31/2016 | 28 | -8 | N/A | -3 | N/A |
| 9/30/2016 | 28 | -8 | N/A | N/A | N/A |
| 6/30/2016 | 29 | -8 | N/A | -4 | N/A |
| 3/31/2016 | 29 | -7 | N/A | -3 | N/A |
| 12/31/2015 | 30 | -6 | N/A | -2 | N/A |
| 9/30/2015 | 30 | -6 | N/A | N/A | N/A |
| 6/30/2015 | 31 | -6 | N/A | -3 | N/A |
| 3/31/2015 | 31 | -6 | N/A | -3 | N/A |
| 12/31/2014 | 31 | -5 | N/A | -3 | N/A |
| 9/30/2014 | 31 | -5 | N/A | -3 | N/A |
| 6/30/2014 | 31 | -5 | N/A | -4 | N/A |
| 3/31/2014 | 31 | -6 | N/A | -4 | N/A |
| 12/31/2013 | 31 | -6 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: E8TN's forecast earnings growth (29% per year) is above the savings rate (1%).
Earnings vs Market: E8TN's earnings (29% per year) are forecast to grow faster than the German market (21.1% per year).
High Growth Earnings: E8TN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: E8TN's revenue (3.9% per year) is forecast to grow slower than the German market (5.6% per year).
High Growth Revenue: E8TN's revenue (3.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: E8TN's Return on Equity is forecast to be low in 3 years time (10.5%).